technologies
Stephanie C. Wu, DPM, MD, PhD,a William Marston, MD,b and David G. Armstrong, DPM, MSc,c
North Chicago, Ill; Chapel Hill, NC; and Tucson, Ariz
Wound repair and regeneration is a highly complex combination of matrix destruction and reorganization. While major
hurdles remain, advances over the past generation have improved the clinician’s armamentarium in the medical and
surgical management of this problem. The purpose of this manuscript is to review the current literature regarding the
pragmatic use of three of the most commonly employed advanced therapies; namely, bioengineered tissue, negative
pressure wound therapy, and hyperbaric oxygen therapy with a focus on the near-term future of wound healing, including
stem cell therapy. ( J Vasc Surg 2010;52:59S-66S.)
Wound repair is an orchestra of highly integrated bio- BIOENGINEERED SKIN AND DERMAL
logical and molecular events of cell migration and prolifer- SUBSTITUTES OR EQUIVALENTS
ation, and of extracellular matrix deposition and remodel- Cell-based technologies to deliver exogenous
ing.1 Certain pathophysiologic and metabolic conditions growth factors to the wound bed. Autogenous and
can alter this normal course of events so that healing is non-autogenous skin grafts, commonly used for the heal-
impaired or delayed, resulting in chronic, nonhealing ing of skin ulcerations, may be associated with a number of
wounds.2,3 Diabetic foot ulcers (DFUs) readily become limitations such as risks of immune rejection, infection
chronic, and the factors that delay wound healing are transmission,6,7 and the creation of a donor site that is at
multiple and relate both to diabetes and to the effects of its risk of developing pain, scarring, infection, and/or delayed
complications.3 The costs associated with the healing of an healing.7 The need for a readily available, non-antigenic
ulcer have been noted to be as high as $45,000; however, tissue that possesses many of the histological and functional
these estimates do not include the deleterious effects on the characteristics of normal human skin spawned the evolu-
patient’s quality of life because of impaired mobility and tion of growing living human tissues for transplantation.
substantial loss of productivity.4 Clearly, the healing of Tissue engineering has revolutionized skin grafting from
ulcerations in a timely manner is of central importance in the initial autograft and allograft preparations to biosyn-
any plan for amputation prevention and limb preserva- thetic and tissue-engineered skin replacements and cell-
tion.5,6 The integration of technological advances with our based therapies. These advanced therapies include cultured
understanding of the complex cellular and biochemical autologous keratinocyte grafts, cultured allogeneic keratin-
mechanisms of wound healing has led to the development ocyte grafts, autologous/allogeneic composites, acellular
of various advanced wound healing modalities, such as collagen matrices, and cellular matrices. A number of prod-
bioengineered skin and tissue equivalents, negative pres- ucts are commercially available, and many others are in
sure wound therapy (NPWT), and hyperbaric oxygen ther- development. The ones that are currently available include
apy. This article examines the latest advances in wound human fibroblast-derived dermal substitute, human fibro-
healing using these three therapeutic categories and as- blast-derived temporary skin substitute, and allogeneic bi-
sesses their implications for clinical practice. layered cultured skin equivalent.
Human fibroblast-derived dermal substitute.
From the Rosalind Franklin University of Medicine and Science;a the
Human fibroblast-derived dermal substitute (Dermagraft,
Department of Surgery, Section of Vascular Surgery, University of North Advanced Biohealing Ltd, La Jolla, Calif) is composed of
Carolina School of Medicine;b and the Department of Surgery, Southern fibroblasts, extracellular matrix, and a bioabsorbable scaf-
Arizona Limb Salvage Alliance (SALSA), University of Arizona College of fold (Fig 1). It is produced by culturing human dermal
Medicine.c
Competition of interest: none.
fibroblast cells derived from newborn foreskin tissue onto a
This article is being co-published in the Journal of Vascular Surgery® and the bioabsorbable polyglactin mesh scaffold.8 As the fibroblasts
Journal of the American Podiatric Medical Association. proliferate to fill the interstices of this scaffold, they secrete
Reprint requests: Dr David G. Armstrong, Southern Arizona Limb Salvage human dermal collagen, matrix proteins, growth factors,
Alliance, University of Arizona College of Medicine, Department of
Surgery, Tucson, AZ 85724 (e-mail: armstrong@usa.net).
glycosaminoglycans, and cytokines to generate a three-
The editors and reviewers of this article have no relevant financial relationships dimensional, allogeneic, human dermal substitute contain-
to disclose per the JVS policy that requires reviewers to decline review of any ing metabolically active, living cells with a preferred, nearly
manuscript for which they may have a competition of interest. parallel alignment of the collagen fibers within human
0741-5214/$36.00
Copyright © 2010 by the Society for Vascular Surgery and the American
dermal substitute.8 The critical dependence of the thera-
Podiatric Medical Association. peutic properties of this living dermal implant on the recov-
doi:10.1016/j.jvs.2010.06.009 ery of protein synthesis, growth factor expression, and
59S
JOURNAL OF VASCULAR SURGERY
60S Wu et al September Supplement 2010
moist gauze dressings (59% vs 0% and 49% vs 8%, respec- plex wounds. Abidia and colleagues randomly assigned 18
tively).31 patients with ischemic non-healing diabetic limb ulcers to
Recently published trials have further demonstrated the 100% oxygen or air at 2.4 atmospheres for 90 minutes in a
wound-healing efficacy of NPWT. Blume and coworkers hyperbaric chamber daily.37 In this double-blind study,
compared the safety and clinical efficacy of NPWT with oxygen and control groups received 30 sessions after which
advanced moist wound therapy (AMWT) to treat diabetic the outcome was measured. In the oxygen group, five of
foot ulcers in a multicenter, randomized, controlled trial. eight ulcers were closed completely, compared to one of
They enrolled 342 subjects, 79% male, with a mean age of the eight control ulcers (P ⫽ .027).
58 years, who were randomized to receive either NPWT or In another prospective study of diabetic foot ulcers,
AMWT and standard off-loading therapy as needed.32 The Kalani et al enrolled 38 patients with non-healing foot
authors noted that a greater proportion of foot ulcers ulcers and basal transcutaneous oxygen levels in the foot
achieved complete ulcer closure with NPWT (73/169; below 40 mm Hg.38 Seventeen patients were treated with
43.2%) than AMWT (48/166; 28.9%) within the 112-day HBO for 40 to 60 sessions, and 21 were treated with
active treatment phase (P ⫽ .007). The Kaplan-Meier standard diabetic ulcer care. Patients were followed for 3
median estimate for 100% ulcer closure was 96 days (95% years. At final follow-up, 76% of patients treated with HBO
confidence interval: 75.0, 114.0) for NPWT and not deter- had healed their DFU, and only 12% required limb ampu-
minable for AMWT (P ⫽ .001). The authors noted no tation. In the standard care group, 48% had healed their
significant difference between the groups in treatment- foot ulcer at 3 years, and 33% required limb amputation.
related complications at 6 months. In 2004, the Cochrane Collaborative reviewed hyper-
Similarly, a 16-week, 18-center, randomized clinical baric oxygen therapy for chronic wounds and concluded
trial conducted by Armstrong and Lavery, involving 162 that HBO reduces the risk of amputation for patients with
diabetic patients with larger and more complex wounds DFU and increases the chance of healing at 1 year.39
than those from previous randomized trials, found that However, it was noted that these recommendations were
NPWT healed more wounds after partial foot amputation based on small, underpowered studies and that further
versus the standard of care (43 [56%] vs 33 [39%]; P ⫽ randomized studies were greatly needed to clarify the ben-
.040). The authors noted that NPWT produced faster efits of this costly therapy. Addressing some of the method-
wound-healing rates (P ⫽ .005) and faster granulation ologic concerns of previous studies, a rather robust double-
tissue formation rates, versus standard of care, based on the blind randomized controlled study conducted by Londahl
time needed to complete closure (P ⫽ .002).33 Resource and coworkers42 suggested improved healing in the active
utilization for patients treated with NPWT also was evalu- HBO group compared with placebo at 1 year in patients
ated in this same study population. Apelqvist34 and co- suffering from complex diabetic foot wounds (52% vs 29%;
workers reported that patients randomized to the NPWT P ⫽ .03). This study used an intent-to-treat analysis for
group required fewer surgical procedures (including de- patients with chronic (⬎3 month duration) neuropathic
bridement) than the control group (43 vs 120; P ⬍ .001), and neuroischemic wounds. All received treatment in a
fewer average number of dressing changes (41 [range, multiplace chamber receiving either active HBO or placebo
6-140] for NPWT versus 118.0 [range, 12-226] for con- (compressed air).
trol MWT [P ⬍ .0001]), and fewer outpatient treatment Further work has been conducted to identify better
visits (4 [range, 0-47] in the NPWT versus 11 [range, decision-making parameters for the use of HBO. Works
0-106] for control, [P ⬍ .05]). This yielded a cost savings have focused on the use of transcutaneous oxygen tension
in excess of $12,800 compared with standard therapy. (TcPO2) as a predictive modality in selecting patients for
Combined with the clinical data, these analyses provide HBO treatment. Specifically, Grolman et al measured
compelling evidence that appropriate use of NPWT is TcPO2 in the ischemic limb of 36 patients breathing room
efficacious and cost-effective in achieving healing of prop- air, followed by 100% O2. They found an increase of
erly selected wounds, both on an inpatient and outpatient TcPO2 in the ischemic foot of ⬎10 torr was associated
basis. with a healing rate of 70%, compared with a healing rate of
Hyperbaric oxygen therapy. Hyperbaric oxygen 11% in those with an increase of ⬍10 torr.40 In a larger
(HBO) has long been considered as a potential treatment study of ischemic and non-ischemic DFUs, Fife and col-
modality for complicated or recalcitrant ulcers. Oxygen has leagues evaluated the use of TcPO2 in 1144 patients. In
been reported to stimulate angiogenesis, enhance fibroblast this study, predictive values were relatively poor, with some
and leukocyte function, and normalize cutaneous micro- patients healing despite low initial and in-chamber
vascular reflexes.35,36 Clinically, HBO has been demon- TcPO2.41
strated to improve transcutaneous pO2 in the limbs of While data, particularly recently, have pointed toward
some patients with ischemic ulcers. Significant side ef- HBO therapy as having some degree of potential benefit, its
fects of treatment are uncommon, but may be severe, cost is high. Patients often travel long distances for daily
including barotraumatic otitis, hyperoxic seizures, and treatments at great cost to themselves and their families.
pneumothorax. Although reported protocols for treatment of ischemic
For the treatment of DFU, one randomized study was limb ulcers vary significantly, most involve a total cost of
particularly influential in supporting use of HBO for com- $15,000 to $40,000. In an assessment for the Canadian
JOURNAL OF VASCULAR SURGERY
64S Wu et al September Supplement 2010
formation of granulation tissue, and elimination of wound 19. Brem H, Balledux J, Bloom T, Kerstein MD, Hollier L. Healing of
exudate.56 Brem et al found that two separate clinical and diabetic foot ulcers and pressure ulcers with human skin equivalent: a
new paradigm in wound healing. Arch Surg 2000;135:627-34.
specialty sites were able to achieve a frequency of complete
20. Newton DJ, Khan F, Belch JJ, Mitchell MR, Leese GP. Blood flow
wound closure of greater than 70% within 6 months via changes in diabetic foot ulcers treated with dermal replacement therapy.
optimal wound preparation.56 Care for a patient with dia- J Foot Ankle Surg 2002;41:233-7.
betic foot ulceration is complex, necessitating collaboration 21. Introduction. Healing chronic wounds: technologic solutions for today
of a multidisciplinary team to achieve treatment goals; such and tomorrow. Adv Skin Wound Care 2000;13(2 Suppl):4-5.
22. Edmonds M; European and Australian Apligraf Diabetic Foot Ulcer
a team must accurately assess and manage current wound
Study Group. Apligraf in the treatment of neuropathic diabetic foot
and patient conditions, optimally manage subsequent com- ulcers. Int J Low Extrem Wounds 2009;8:11-8.
plications, and aim to promote shorter healing time. Ad- 23. Steinberg JS, Edmonds M, Hurley DP Jr, King WN. Confirmatory data
vanced wound healing modalities, when used appropri- from EU study supports Apligraf for the treatment of neuropathic
ately, may serve as useful components of the wound diabetic foot ulcers. J Am Podiatr Med Assoc 2010;100:73-7.
24. Molecule of the month: Apligraf living human skin equivalent. Drug
management algorithm.
News Perspect 1998;11:43.
25. Dolynchuk K, Hull P, Guenther L, Sibbald RG, Brassard A, Cooling M,
et al. The role of Apligraf in the treatment of venous leg ulcers. Ostomy
REFERENCES
Wound Manage 1999;45:34-43.
1. Falanga V. Classifications for wound bed preparation and stimulation of 26. Fagrell B, Jorneskog G, Intaglietta M. Disturbed microvascular reactiv-
chronic wounds. Wound Repair Regen 2000;8:347-52. ity and shunting–a major cause for diabetic complications. Vasc Med
2. Mustoe TA, O’Shaughnessy K, Kloeters O. Chronic wound pathogen- 1999;4:125-7.
esis and current treatment strategies: a unifying hypothesis. Plast Re- 27. Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost
constr Surg 2006;117(7 Suppl):35S-41S. effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmaco-
3. Marston WA; Dermagraft Diabetic Foot Ulcer Study Group. Risk economics 2003;21:1171-83.
factors associated with healing chronic diabetic foot ulcers: the impor- 28. Langer A, Rogowski W. Systematic review of economic evaluations of
tance of hyperglycemia. Ostomy Wound Manage 2006;52:26-8, 30, 32 human cell-derived wound care products for the treatment of venous
passim. leg and diabetic foot ulcers. BMC Health Serv Res 2009;9:115.
4. Paquette D, Falanga V. Leg ulcers. Clin Geriatr Med 2002;18:77-88, vi. 29. McCallon SK, Knight CA, Valiulus JP, Cunningham MW, McCulloch
5. Veves A, Falanga V, Armstrong DG, Sabolinski ML; Apligraf Diabetic JM, Farinas LP. Vacuum-assisted closure versus saline-moistened gauze
Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the in the healing of postoperative diabetic foot wounds. Ostomy Wound
management of noninfected neuropathic diabetic foot ulcers: a prospec- Manage 2000;46:28-32, 34.
tive randomized multicenter clinical trial. Diabetes Care 2001;24: 30. Armstrong DG, Lavery LA, Abu-Rumman P, Espensen EH, Vazquez
290-5. JR, Nixon BP, et al. Outcomes of subatmospheric pressure dressing
6. Lee KH. Tissue-engineered human living skin substitutes: development therapy on wounds of the diabetic foot. Ostomy Wound Manage
and clinical application. Yonsei Med J 2000;41:774-9. 2002;48:64-8.
7. Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin. Current 31. Eginton MT, Brown KR, Seabrook GR, Towne JB, Cambria RA. A
status in wound healing. Am J Clin Dermatol 2001;2:305-13.
prospective randomized evaluation of negative-pressure wound dress-
8. Marston WA. Dermagraft, a bioengineered human dermal equivalent
ings for diabetic foot wounds. Ann Vasc Surg 2003;17:645-9.
for the treatment of chronic nonhealing diabetic foot ulcer. Expert Rev
32. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of
Med Devices 2004;1:21-31.
negative pressure wound therapy using vacuum-assisted closure with
9. Mansbridge J, Liu K, Patch R, Symons K, Pinney E. Three-dimensional
advanced moist wound therapy in the treatment of diabetic foot ulcers:
fibroblast culture implant for the treatment of diabetic foot ulcers:
a multicenter randomized controlled trial. Diabetes Care 2008;31:
metabolic activity and therapeutic range. Tissue Eng 1998;4:403-14.
631-6.
10. Mansbridge J. Skin substitutes to enhance wound healing. Expert Opin
33. Armstrong DG, Lavery LA. Negative pressure wound therapy after
Investig Drugs 1998;7:803-9.
partial diabetic foot amputation: a multicentre, randomised controlled
11. Marston WA, Hanft J, Norwood P, Pollak R; Dermagraft Diabetic Foot
trial. Lancet 2005;366:1704-10.
Ulcer Study Group. The efficacy and safety of Dermagraft in improving
34. Apelqvist J, Armstrong DG, Lavery LA, Boulton AJM. Resource utili-
the healing of chronic diabetic foot ulcers: results of a prospective
randomized trial. Diabetes Care 2003;26:1701-5. zation and economic costs of care based on a randomized trial of
12. Hanft JR, Surprenant MS. Healing of chronic foot ulcers in diabetic vacuum-assisted closure therapy in the treatment of diabetic foot
patients treated with a human fibroblast-derived dermis. J Foot Ankle wounds. Am J Surg 2008;195:782-8.
Surg 2002;41:291-9. 35. Kuffler DP. Hyperbaric oxygen therapy: an overview. J Wound Care
13. Browne AC, Vearncombe M, Sibbald RG. High bacterial load in 2010;19:77-9.
asymptomatic diabetic patients with neurotrophic ulcers retards wound 36. Goldman RJ. Hyperbaric oxygen therapy for wound healing and limb
healing after application of Dermagraft. Ostomy Wound Manage 2001; salvage: a systematic review. PM R 2009;1:471-89.
47:44-9. 37. Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM,
14. Allenet B, Parée F, Lebrun T, Carr L, Posnett J, Martini J, et al. et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower
Cost-effectiveness modeling of Dermagraft for the treatment of diabetic extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc
foot ulcers in the French context. Diabetes Metab 2000;26:125-32. Endovasc Surg 2003;25:513-8.
15. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment 38. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric
(Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term
Clin Interv Aging 2007;2:93-8. follow-up. J Diabetes Complications 2002;16:153-8.
16. De SK, Reis ED, Kerstein MD. Wound treatment with human skin 39. Kranke P, Bennett M, Roeckl-Wiedmann I, Debus S. Hyperbaric
equivalent. J Am Podiatr Med Assoc 2002;92(1):19-23. oxygen therapy for chronic wounds. Cochrane Database Syst Rev
17. Trent JF, Kirsner RS. Tissue engineered skin: Apligraf, a bi-layered 2004;(2):CD004123.
living skin equivalent. Int J Clin Pract 1998;52:408-13. 40. Grolman RE, Wilkerson DK, Taylor J, Allinson P, Zatina MA. Trans-
18. Donohue KG, Carson P, Iriondo M, Zhou L, Saap L, Gibson K, et al. cutaneous oxygen measurements predict a beneficial response to hyper-
Safety and efficacy of a bilayered skin construct in full-thickness surgical baric oxygen therapy in patients with nonhealing wounds and critical
wounds. J Dermatol 2005;32:626-31. limb ischemia. Am Surg 2001;67:1072-9; discussion 1080.
JOURNAL OF VASCULAR SURGERY
66S Wu et al September Supplement 2010
41. Fife CE, Buyukcakir C, Otto GH, Sheffield PJ, Warriner RA, Love TL, 49. Badiavas EV, Ford D, Liu P, Kouttab N, Morgan J, Richards A, et al.
et al. The predictive value of transcutaneous oxygen tension measure- Long-term bone marrow culture and its clinical potential in chronic
ment in diabetic lower extremity ulcers treated with hyperbaric oxygen wound healing. Wound Repair Regen 2007;15:856-65.
therapy: a retrospective analysis of 1,144 patients. Wound Repair Regen 50. Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, et al.
2002;10:198-207. Autologous bone marrow-derived cultured mesenchymal stem cells
42. Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxy- delivered in a fibrin spray accelerate healing in murine and human
gen therapy facilitates healing of chronic foot ulcers in patients with cutaneous wounds. Tissue Eng 2007;13:1299-312.
diabetes. Diabetes Care 2010;33:998-1003. 51. Steed DL. Clinical evaluation of recombinant human platelet-derived
43. Chuck AW, Hailey D, Jacobs P, Perry DC. Cost-effectiveness and growth factor for the treatment of lower extremity diabetic ulcers.
budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot Diabetic Ulcer Study Group. J Vasc Surg 1995;21:71-8.
ulcers. Int J Technol Assess Health Care 2008;24:178-83.
52. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of
44. Badiavas EV, Falanga V. Treatment of chronic wounds with bone
Promogran (a collagen/oxidized regenerated cellulose dressing) vs
marrow-derived cells. Arch Dermatol 2003;139:510-6.
standard treatment in the management of diabetic foot ulcers. Arch
45. Deng J, Petersen BE, Steindler DA, Jorgensen ML, Laywell ED.
Surg 2002;137:822-7.
Mesenchymal stem cells spontaneously express neural proteins in
53. Gentzkow GD, Iwasaki SD, Hershon KS. Use of Dermagraft, a cultured
culture and are neurogenic after transplantation. Stem Cells 2006;24:
1054-64. human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19:
46. Fathke C, Wilson L, Hutter J, Kapoor V, Smith A, Hocking A, et al. 350-4.
Contribution of bone marrow-derived cells to skin: collagen deposition 54. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for
and wound repair. Stem Cells 2004;22:812-22. diabetic foot ulcers. Lancet 2005;366:1725-35.
47. McFarlin K, Gao X, Liu YB, Dulchavsky DS, Kwon D, Arbab AS, et al. 55. Armstrong DG, Boulton AJ. Pressure offloading and “advanced”
Bone marrow-derived mesenchymal stromal cells accelerate wound wound healing: isn’t it finally time for an arranged marriage? Int J Low
healing in the rat. Wound Repair Regen 2006;14:471-8. Extrem Wounds 2004;3:184-7.
48. Bauer SM, Goldstein LJ, Bauer RJ, Chen H, Putt M, Velazquez OC. 56. Brem H, Balledux J, Sukkarieh T, Carson P, Falanga V. Healing of
The bone marrow-derived endothelial progenitor cell response is im- venous ulcers of long duration with a bilayered living skin substitute:
paired in delayed wound healing from ischemia. J Vasc Surg 2006;43: results from a general surgery and dermatology department. Dermatol
134-41. Surg 2001;27:915-9.